Trial Profile
A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Wolman disease
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease; Synageva BioPharma
- 21 Nov 2020 This trial has been Completed in Italy, according to European Clinical Trials Database record.
- 29 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 15 Feb 2019 The trial has been completed in UK.